Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has issued a notice of allowance for a company patent application covering "certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates, for in vivo delivery."
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.